ATE272650T1 - Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes - Google Patents

Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes

Info

Publication number
ATE272650T1
ATE272650T1 AT00912766T AT00912766T ATE272650T1 AT E272650 T1 ATE272650 T1 AT E272650T1 AT 00912766 T AT00912766 T AT 00912766T AT 00912766 T AT00912766 T AT 00912766T AT E272650 T1 ATE272650 T1 AT E272650T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
analogues
inhibiting peptides
peptides
Prior art date
Application number
AT00912766T
Other languages
English (en)
Inventor
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Original Assignee
Uutech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9907216A external-priority patent/GB9907216D0/en
Priority claimed from GB9917565A external-priority patent/GB9917565D0/en
Application filed by Uutech Ltd filed Critical Uutech Ltd
Application granted granted Critical
Publication of ATE272650T1 publication Critical patent/ATE272650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00912766T 1999-03-29 2000-03-29 Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes ATE272650T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9907216A GB9907216D0 (en) 1999-03-29 1999-03-29 Peptide
GB9917565A GB9917565D0 (en) 1999-07-27 1999-07-27 Peptide
PCT/GB2000/001089 WO2000058360A2 (en) 1999-03-29 2000-03-29 Analogs of gastric inhibitory peptide and their use for treatment of diabetes

Publications (1)

Publication Number Publication Date
ATE272650T1 true ATE272650T1 (de) 2004-08-15

Family

ID=26315353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912766T ATE272650T1 (de) 1999-03-29 2000-03-29 Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes

Country Status (11)

Country Link
US (4) US6921748B1 (de)
EP (1) EP1171465B1 (de)
AT (1) ATE272650T1 (de)
AU (1) AU3441400A (de)
CA (1) CA2367856C (de)
DE (2) DE60012721D1 (de)
DK (1) DK1171465T3 (de)
ES (1) ES2225107T3 (de)
MX (1) MXPA01009805A (de)
PT (1) PT1171465E (de)
WO (1) WO2000058360A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ES2225107T3 (es) * 1999-03-29 2005-03-16 Uutech Limited Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003237933A1 (en) * 2002-06-11 2003-12-22 Cellartis Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2489323A1 (en) * 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
KR20060009902A (ko) 2003-05-05 2006-02-01 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
KR20120007079A (ko) 2003-10-15 2012-01-19 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
KR20070073896A (ko) 2004-10-25 2007-07-10 사이토스 바이오테크놀로지 아게 위 억제 폴리펩티드(ｇｉｐ) 항원 어레이 및 그의 용도
ATE528005T1 (de) 2005-01-10 2011-10-15 Cortendo Ab Publ 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
AU2006311830B2 (en) 2005-11-03 2013-03-14 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2664800A1 (en) 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
AU2007317435A1 (en) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
EP1935420A1 (de) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP5393489B2 (ja) * 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
MX2009011059A (es) 2007-04-13 2009-11-26 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2110374A1 (de) 2008-04-18 2009-10-21 Merck Sante Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
PE20100255A1 (es) 2008-06-17 2010-04-25 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AU2009264242A1 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
KR20130133104A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
CN102171243A (zh) * 2008-08-07 2011-08-31 益普生制药股份有限公司 N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
EP2328922A4 (de) 2008-08-07 2013-01-02 Ipsen Pharma Sas Analoga des glucoseabhängigen insulinotropen polypeptids
AU2009280012B2 (en) 2008-08-07 2012-12-06 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
EP2358200A4 (de) 2008-11-17 2012-05-16 Merck Sharp & Dohme Substituierte bizyklische amine für die behandlung von diabetes
AU2009335711A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
EP2376521B1 (de) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Auf amid basierende insulin-rpodrugs
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
BRPI0922969A2 (pt) * 2008-12-19 2019-09-24 Univ Indiana Res & Tech Corp pró-farmaco de amida baseado na superfamília de glucagon peptídeo.
JP2012522748A (ja) 2009-04-01 2012-09-27 ノバルティス アーゲー ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体
IN2012DN00377A (de) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011014680A2 (en) * 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Gastric inhibitory peptide variants and their uses
WO2011039358A1 (en) 2009-10-01 2011-04-07 Novartis Ag Pyrazole derivatives which modulate stearoyl-coa desaturase
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
EP2512503A4 (de) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Coagonisten des glucagon/glp-1 rezeptors
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2012168464A1 (en) * 2011-06-10 2012-12-13 Universität Bern Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof
DK2723367T3 (en) 2011-06-22 2017-07-17 Univ Indiana Res & Tech Corp Glucagon / GLP-1 receptor-CO-AGONISTS
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2793932B1 (de) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Insulinanaloga auf ctp-basis zur behandlung von diabetes
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
TWI599575B (zh) 2012-06-21 2017-09-21 印第安納大學科技研究公司 表現ｇｉｐ受體活性之胰高血糖素類似物
FR2994848B1 (fr) 2012-08-30 2014-08-22 Univ Paris Curie Traitement de l'arthrose par les hormones incretines ou leurs analogues
EP3395358B1 (de) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulinanalogdimere
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
PL3189072T3 (pl) 2014-09-05 2019-04-30 Univ Copenhagen Analogi peptydowe gip
WO2016049174A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Lipidated amide-based insulin prodrugs
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
ES2972848T3 (es) 2017-05-31 2024-06-17 The Univ Of Copenhagen Análogos de péptido GIP de acción prolongada
EP3788063B1 (de) 2018-05-04 2023-08-09 Novo Nordisk A/S Gip-derivate und verwendungen davon
WO2020074958A1 (en) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5998204A (en) * 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ES2225107T3 (es) * 1999-03-29 2005-03-16 Uutech Limited Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.

Also Published As

Publication number Publication date
EP1171465A2 (de) 2002-01-16
MXPA01009805A (es) 2004-07-30
US7326688B2 (en) 2008-02-05
EP1171465B1 (de) 2004-08-04
CA2367856A1 (en) 2000-10-05
DE60012721D1 (de) 2004-09-09
ES2225107T3 (es) 2005-03-16
DE60012721T2 (de) 2005-09-15
US20050277590A1 (en) 2005-12-15
DK1171465T3 (da) 2004-12-13
US7666838B2 (en) 2010-02-23
US20100267628A1 (en) 2010-10-21
US6921748B1 (en) 2005-07-26
DE60012721T4 (de) 2010-09-09
CA2367856C (en) 2013-10-15
WO2000058360A3 (en) 2001-01-25
US20080161244A1 (en) 2008-07-03
AU3441400A (en) 2000-10-16
WO2000058360A2 (en) 2000-10-05
PT1171465E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
ATE272650T1 (de) Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
IL160319A0 (en) Compositions and method of treating diabetes
DE60121808D1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
WO2005082928A3 (en) Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
EP2517722A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
DE122008000046I1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1492579T3 (da) Medicinske proteseindretninger med forbedret bioforligelighed
FR12C0004I1 (de)
MY142777A (en) Substituted indole-o-glucosides
YU68002A (sh) Modifikovani faktor viii
UA87991C2 (en) Substituted indole-o-glucosides
ATE330970T1 (de) Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids
DE60128701D1 (en) Claudin polypeptide
DE60139466D1 (de) Behandlung von diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE602006017806D1 (de) Behandlung von neurodegeneration
WO2005011725A3 (fr) Agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EP2275118A3 (de) Pankreas spezifische proteine
NZ514691A (en) Method to type prion proteins
EP1467207A4 (de) Screening-verfahren
EP1414794A4 (de) Allylmercaptocaptoprilverbindungen und deren verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1171465

Country of ref document: EP

REN Ceased due to non-payment of the annual fee